Cargando…

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options

Post-transplant lymphoproliferative disease (PTLD) is a serious complication occurring as a consequence of immunosuppression in the setting of allogeneic hematopoietic stem cell transplantation (alloHSCT) or solid organ transplantation (SOT). The majority of PTLD arises from B-cells, and Epstein–Bar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clerico, Michele, Dogliotti, Irene, Aroldi, Andrea, Consoli, Chiara, Giaccone, Luisa, Bruno, Benedetto, Cavallo, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784583/ https://www.ncbi.nlm.nih.gov/pubmed/36556158 http://dx.doi.org/10.3390/jcm11247542

Ejemplares similares

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience
por: Busca, Alessandro, et al.
Publicado: (2022)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications
por: Lia, Giuseppe, et al.
Publicado: (2020)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
por: Compagno, Francesca, et al.
Publicado: (2020)

Bacterial Bloodstream Infections after Allogeneic Hematopoietic Stem Cell Transplantation: Etiology, Risk Factors and Outcome in a Single-Center Study
por: Gill, Jessica, et al.
Publicado: (2023)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?
por: Lia, Giuseppe, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
por: Fonseca-Hial, Ana Marcela Rojas, et al.
Publicado: (2016)

Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs
por: Bruno, Benedetto, et al.
Publicado: (2010)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Cost-Effectiveness of Targeted Prophylaxis among Allogenic Stem Cell Transplant Recipients
por: Shbaklo, Nour, et al.
Publicado: (2023)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
por: Liu, Li, et al.
Publicado: (2020)

Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience
por: Sakamoto, Hikaru, et al.
Publicado: (2019)

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation
por: Aydin, Semra, et al.
Publicado: (2020)

Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients
por: Liu, Yan, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Posttransplant Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation in Korea
por: Park, Sun Hee, et al.
Publicado: (2006)

Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach
por: Giaccone, Luisa, et al.
Publicado: (2020)

Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
por: Zhu, Cheng-ying, et al.
Publicado: (2019)

Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3–ITD-mutated acute myeloid leukemia
por: Aydin, Semra, et al.
Publicado: (2022)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
por: Lau, Eric, et al.
Publicado: (2021)

COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment
por: Clerico, Michele, et al.
Publicado: (2021)

Hematopoietic Stem Cell Transplantation after Posttransplant Lymphoproliferative Disorder
por: Kim, Min Joo, et al.
Publicado: (2010)

Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
por: Butera, Sara, et al.
Publicado: (2021)

Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children
por: Offor, Ugonna T, et al.
Publicado: (2023)

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
por: Yang, Ting-Ting, et al.
Publicado: (2021)

Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
por: Du, Wei, et al.
Publicado: (2018)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy
por: Kim, Hee-Je, et al.
Publicado: (2021)

Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2021)

Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation
por: Bonifazi, Francesca, et al.
Publicado: (2020)

Endobronchial Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Transplantation
por: Feuillet, S., et al.
Publicado: (2009)

Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)
por: Hong, Jennifer, et al.
Publicado: (2021)

Hematopoietic cell transplantation for asymptomatic X-linked lymphoproliferative syndrome type 1
por: Tamura, Akihiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d5gbnr90gf8ankbhejnlbkeqna